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Abstract—Deficiencies of antithrombin (AT), protein C (PC) or protein S (PS), and activated protein C resistance (APCR)
are very well-established coagulation defects predisposing to venous thromboembolism (VTE). We performed a
retrospective cohort family study to assess the risk for VTE in individuals with AT, PC, or PS deficiency, or APCR. Five
hundred thirteen relatives from 9 Italian centers were selected from 233 families in which the proband had had at least
l episode of VTE. We calculated the incidence of VTE in the whole cohort and in the subgroups after stratification by
age, sex, and defect. The overall incidence of VTE (per 100 patient-years) in the group of relatives was 0.52. It was 1.07
for AT, 0.54 for PC, 0.50 for PS, 0.30 for APCR, and 0.67 in the group with a double defect. The incidence was
associated with age, but not with sex. The mean age at onset was between 30 and 40 years for all the coagulation defects.
Women had the peak of incidence in the age ränge of 21 to 40 years, earlier than men. The lifetime risk for VTE was
4.4 for AT versus APCR, 2.6 for AT versus PS, 2.2 for AT versus PC, 1.9 for PC versus APCR, and 1.6 for PS versus
APCR. AT deficiency seems to have a higher risk for VTE than the other genetic defects. There is a relation between
age and occurrence of thrombosis for both men and women. The latter had the peak of incidence earlier than the former.
(Arterioscler Thromb Vase Biol. 1999;19:1026-1033.)
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Inherited thrombophilia is defined äs a genetically deter-mined tendency to venous thromboembolism (VTE). It is
characterized by onset at an early age, a frequent recurrence,
and a family history (each one present in different combina-
tion with the others).1 It has been known for several decades
that deficiencies of the natural coagulation inhibitors, such äs
antithrombin (AT), protein C (PC), and protein S (PS), are
associated with inherited thrombophilia.2 Several studies
have demonstrated that mutations in the genes encoding AT,
PC, and PS are strong risk factors for thrombosis, but their
prevalence in patients with venous thrombosis is low (3% to
10%).2~6 Recently, a poor anticoagulant response to activated
PC has been described irt patients with inherited thrombo-
philia and is äs yet the most common inherited risk factor for
thrombosis known (20% to 40% prevalence among patients
with venous thrombosis).7·8 Activated protein C resistance
(APCR) is caused by the presence of a mutant factor V
molecule (factor V:Q506) in which a single point mutation
leads to a Substitution of Arg506 by Gin in l of the APC
cleavage sites.9 Its relatively high frequency in populations of
white origin (3% to 13%), and the fact that some homozy-
gotes for APCR remain asymptomatic for a long time led to
the conclusion that this coagulation defect is mild in compar-
ison with the inherited deficiencies of the coagulation inhib-
itors. To date, only l clinical study on unselected cases of
VTE (Leiden Thrombophilia Study)8-10 is available compar-
ing directly APCR and the other coagulation inhibitor defi-
ciencies. In this population-based case-control study, the risk
for VTE was increased 7-fold in both PC deficiency and
APCR carriers, and increased 2-fold in AT deficiency carri·
ers, but no association between PS deficiency and VTE was
demonstrated. The limit of this study is the small size of AT,
PC, and PS carriers. A cohort study might assure a sufficienl
number of subjects also for rare defects, such äs those of
coagulation inhibitors. For these reasons, the Italian Research
Group on Inherited Thrombophilia (GIRTE) has been K-
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cently constituted among clinical centers known to have
interest and expertise in the diagnosis and management of
inherited coagulation disorders, to form a national registe? for
the study of inherited thrombophilia. Until now, 9 centers
have taken part in this project. We performed a retrospective
cohort family study of 513 relatives from 233 kindreds with
inherited deficiency of AT, PC, or PS, or with APCR, in
which the proband had had at least l episode of VTE. The
main objectives were (1) to assess the lifetime risk for VTE
in subjects with inherited thrombophilia, (2) to describe the
clinical manifestations in these thrombophilic subjects, and




After several meetings about the aims of the study, each center
received a floppy disk with a database (made by using the program
Clinix 3.1, Softwarehouse of Maggiore Hospital) to fill in with all the
Information about thrombophilic subjects, ie, subjects with l of the
congenital deficiencies well established to be associated with VTE
(AT, PC, PS, or APCR). The file was divided into the following 5
main parts: patient identification (coded name, age, sex, whether
proband or relative, and type[s] of coagulation defect), pedigree
(number of family members studied, number of subjects with
deficiency, and number of members with thrombosis), history of
thrombosis (type of event[s], age at each event, diagnostic methods
used to detect thrombosis, and risk factorfs] for each event), history
of exposure to risk factors, and laboratory results. All computerized
data were returned to the coordinating center (Angelo Bianchi
Bonomi Hemophilia and Thrombosis Center of Milan) and entered in
a single file.
Study Design
Families were selected based on the probands who came to each
participating center between January 1978 and March 1996 with at
least l episode of VTE. We selected only families for which the
inheritance of the coagulation defect was demonstrated (at least 2
family members, including the proband, had to be carriers of the
defect). In all cases, history of thrombosis and of exposure to risk
factors was recorded before the laboratory diagnosis was made. As
VTE, we referred to any episode of deep vein thrombosis (ie,
thrombosis affecting the deep veins of the lower and upper extrem-
ities, the superior and inferior cava vein, the cerebral veins, and the
portal-mesenteric circulation) and/or pulmonary embolism. As in-
strumental diagnosis of VTE, we accepted all diagnoses made by
venography, compression ultrasound, color Doppier, impedance
plethysmography, ventilation-perfusion lung scan, pulmonary an-
giography, CT scan, and MRI scan. Diagnosis made without using
these tests was classified äs clinical. However, clinically diagnosed
VTE was considered "certain" if at least l of the following
conditions was satisfied: (1) the patient had a recurrence of VTE,
diagnosed instrumentally, or (2) there was an objective demonstra-
tion of a postphlebitic syndrome after that episode. Diagnosis of
superficial vein thrombosis (SVT) was based on clinical Symptoms.
Arterial thrombosis was diagnosed by clinical signs and objective
methods, ie, ehest pain, high levels of myocardial enzymes and
electrocardiography for myocardial infarction, CT scan or MRI for
ischemic strokes, and focal neurological signs during <24 hours for
transient ischemic attack.
As risk factors for VTE, we considered surgery (only when total
anesthesia was administered), pregnancy, puerperium, oral contra-
ceptives intake, plaster casts (excluding those of the upper extrem-
ities), trauma, and immobilization in bed for >10 days. When a
thrombosis was not associated with a triggering factor, the episode
was classified äs "idiopathic."
After a descriptive analysis of our population in toto, we started a
retrospective cohort study, considering VTE äs the end point. To
avoid bias, we focused our attention only on the group of relatives.
For all centers the follow-up extended from the date of birth of
subjects to either the date of the first episode of VTE, if any, or April
1996.
Patients
We received Information on 1143 subjects from the 9 Italian centers;
178 probands (16 AT, 29 PC, 29 PS, 93 APCR, l heparin cofactor
II, and 10 with double defect) were excluded because the defect was
not demonstrated in other family members; ie, in 124 cases the
proband was the only family member studied, whereas in 54 cases at
least l relative other than the index case was studied, but the
inheritance of the defect was not confirmed. Nineteen patients (l
proband and 18 relatives) were excluded because no complete
Information about history of thrombosis was available. Fifty-six
probands and their 144 relatives were not considered in the analysis
because the index patient had no episodes of VTE. At the end, 746
eligible subjects with demonstrated inherited thrombophilia were
available, ie, 233 probands (31%) and 513 relatives (69%). The
average number of study subjects per family was 3.2 (ränge, 2 to 11
subjects). Total patient-years were 26 151 (6609 for probands and
19 542 for relatives). The number of subjects per type of defect was
129 with AT, 145 PC, 138 PS, 309 APCR, and 25 with a double
defect. Of the 513 relatives, 95 had AT, 102 PC, 93 PS, 209 APCR,
and 14 had a double defect. Type I deficiency was represented in the
81% of AT, 95% of PC, and 100% of PS, whereas type II deficiency
was found in 19% of AT and 5% of PC. Homozygosity was found in
3 patients with PC deficiency (2 probands and l relative, all
symptomatic), whereas no patient with AT or PS was homozygous.
Among the 306 carriers of factor V:Q506 mutation, 295 (96%) were
heterozygous and 11 (4%) homozygous. Of the latter, 5 were
probands (all symptomatic) and 6 were relatives (l symptomatic and
5 asymptomatic). In 76% of families with AT, 67% with PC, 82%
with PS, 75% with APCR, and 82% with double defect, l or >1
family member was affected, other than the proband.
In 8% of all subjects with a first episode of VTE, no Information
was available about the type of diagnosis. In the other cases, the
diagnosis was instrumental in 76% and clinical in 24% of VTE.
Considering only relatives with at least l episode of VTE (n =106),
64 (60%) received instrumental diagnosis and 42 (40%) clinical
diagnosis. For 15 of the latter, VTE was in any case considered
certain with reference to the inclusion criteria mentioned above. So,
for 79 of 106 subjects (75%) VTE was confirmed, and for 27 of 106
(25%) it was uncertain.
Blood Collection and Laboratory Methods
All the study subjects (both probands and relatives) received a
complete screening for all the coagulation defects that we studied.
Also, those patients receiving a diagnosis before 1993 (the year in
which APCR was discovered) were contacted again to obtain blood
samples and complete the screening. Because of the nature of the
study (multicenter retrospective), assays for AT, PC, PS, and APCR
changed during the years and in the different centers. However, all
the participating centers are expert in the diagnosis of congenital
coagulation disorders and participate with proficiency at least annu-
ally in quality control laboratory exercises. The diagnostic approach
to detect a deficiency of anticoagulant proteins (AT, PC, and PS)
followed guidelines previously published in detail." In brief, a
functional assay was first made and then, if the results of this assay
were low, the antigenic concentration of the protein was determined
by either enzyme immunoassay or radioimmunoassay, to differenti-
ate type I (quantitative) from type II (qualitative) deficiency. The
only exception was for PS deficiency, which was diagnosed based on
low levels of free PS antigen. APCR was measured by using an
APTT-based clotting method äs previously described.12 In 306
(94%) of the 327 total subjects with APCR the defect was confirmed
with a genetic lest for demonstration of factor V:Q506 mutation,9 and
in 21 (6%) only the functional test was performed.
Statistical Analysis
The incidence of VTE was estimated by dividing the number of
episodes in each group by the total number of patient-years in that
group. Only the first thrombotic event of each subject has been
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Coagulation Defect
AT PC
No. of families 34 43
No. of relatives 95 102
Males/females 48/47 52/50





No. (%) 38 (40) 35 (34)
Males/females 16/22 12/23
Type of 1 st thrombosis, No. (%)
VTE 35 (92) 22 (63)
SVT 3 (8) 8 (23)
Arterial thrombosis 0 5 (1 4)
considered. In the calculation of relative risk (RR), we used 95%
confidence interval (CI) according to Woolf.n Survival analysis was
performed by the Kaplan-Meier method and with the Cox
proportional-hazards model, which yields a hazard ratio (and its 95%
CI) for VTE, adjusted for age, sex (0 for male and 1 for fernale), and
age of proband at the first episode of VTE (0 for s20 years, 1 for 21
to 45 years, and 2 for >45 years). The hazard ratio reflects the
relative risk of thrombosis for one defect compared with another one,
adjusted for the other variables in the model. Patients with a double
defect were excluded from survival analysis.
Results
Clinical Manifestations
Three hundred eighty-two of the 746 subjects of the whole
cohort were symptomatic (51%), ie, 233 probands (99 males
and 134 females) and 149 relatives (65 males and 84
females). Table 1 shows the main characteristics of the study
population of relatives. The prevalence of thrombosis was
29% (149/513). For AT-deficient relatives, VTE occurred
most frequently äs the first thrombotic event (35 of 38
subjects, 92%), compared with SVT (3 of 38 subjects, 8%),
and arterial thrombosis (0 of 38 subjects). For the other
groups this difference was less evident; in particular, in
APCR relatives 21 of the 42 first episodes (50%) were VTE,
1 1 of 42 (26%) were SVT, and 10 of 42 (24%) were arterial
thromboses. The prevalence of pulmonary embolism at the
first episode was 17% for AT, 7% for PC, 10% for PS, and
7% for APCR. No episode of pulmonary embolism was found
in the 4 cases with a double defect.
Incidence of VTE
The overall incidence of VTE (per 100 patient-years) was 3.4
for probands and 0.52 for relatives. The mean age at tKe onset
of VTE was 29.4 yeajs (ränge, 0 to 71 years) for probands and
35.8 years (ränge, 8 to 81 years) for relatives. Table 2 shows
that the age of probands and the age of relatives at the first
episode of VTE are positively related, whereas the incidence
of VTE in the relatives group is negatively related to the age
of probands; the relation is more evident in the last age group
of probands (>45 years). Table 3 gives the incidences of
VTE for the strata of defects in the population of relatives. It
PS APCR Double Defect Total
45 100 11 233
93 209 14 513 1
42/51 82/127 8/6 232/281 1
38.6 42.0 35.0 39.5
3-81 3-95 4-67 1-95
37 40 33 39
30(32) 42(20) 4(29) 149(29)
20/10 14/28 3/1 65/84
18(60) 21(50) 3(75) 99(66)
8(27) 11(26) 1(25) 31(21)
4(13) 10(24) 0 19(13)
shows the highest incidence in the AT group (1.07%/y) and
the lowest incidence in the APCR group (0.30%/y). The mean
age at the onset was similar for all groups, ranging from 33 to
39 years, except for the group with a double defect, in which
it was the lowest (25 years; ränge, 15 to 41 years). The
stratification by sex did not show differences between men
and women (incidence, 0.52%/y for both). The mean age al
the first episode was 36.5 years (median 36; ränge, 10 to 69
years) for men and 35.1 years (median 30; ränge, 8 to 8l
years) for women. Table 4 shows incidences of VTE for strata
of ages and RR of VTE for each stratum compared with the
first age ränge (<20 years). There was an increased risk for
VTE in the second age group (21 to 40 years), and afterward
the risk became more or less constant. Table 5 represents the
same data after stratification by sex. Women had peak of
incidence at a younger age than men (age ränge, 21 to 40






















age ranges of 21 to 40 for women versus men (0.96%/y I
versus 0.63 %/y; RR=1.5 [95% CI, 0.9 to 2.7]) and 41 to 60 1 *f
m (l 1 1
for men versus women (1.1%/y versus 0.63%/y; RR=1.7 |
[95% CI, 0.85 to 3.4]).
Survival analysis confirmed these data. The risk for VTE in
the AT group, adjusted for age, sex, and age of proband at the
time of the first VTE, was 4-fold greater than that in the
>PCR group (hazard ratio, 4.4 [95% CI, 2.5 to 7.7];
P<0.0001), 3-fold than in the PS group (hazard ratio, 2.6 [1.4
to 4.6]; P=0.002), and 2-fold than in the PC group (hazard
ratio, 2,2 [1.2 to 4.0]; P=0.01). The risk was 2 times higher
TABLE 2. Relation Between the Age of Probands and the Age
of Relatives at the First Episode of VTE
-
Median Age Incidence
Age of Probands Mean Age (ränge) of of Relatives of VTE in
at First VTE Relatives at First at First the Group
(Years) VTE (Years) VTE (Years) of Relatives
£20(n=58) 34.3(8-77) 30 0.62
21-45 (n = 151) 35.5(15-81) 33 0.51
>45(n=24) 42.9(15-67) 40 0.38___
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TABLE 3. Incidence* of VTE in the Whole Study Cohort and in Different Types of



















































*For each subject only the first thrombotic event has been considered.
fPer 100 patient-years.
in the PC group than in the APCR group (hazard ratio, 1.9
[1.1 to 3.4]; P=0.03). No difference was found between the
PS group and the APCR group (hazard ratio, 1.6 [0.86 to 3.0];
P=0.14). The Figure shows thrombosis-free survival curves
for carriers of inhibitor deficiencies or APCR.
Considering only relatives with a certain first episode of
VTE (n=79), the total incidence became 0.41 per 100
patient-years (0.84 for AT, 0.46 for PC, 0.40 for PS, and 0.24
for APCR). Results of survival analysis did not change
substantially (data not shown).
Arterial Thromboses
A total of 26 first episodes of arterial thrombosis were
recorded in the population of relatives (4 in the AT group, 6
in the PC group, 5 in the PS group, 10 in the APCR group,
and l in the group with a double defect). The types of clinical
manifestation were acute myocardial infarction (n= 10; 2 AT,
3 PC, 2 PS, and 3 APCR), stroke (n=8; 2 AT, 2 PS, and 4
APCR), transient ischemic attack (n=3; l PC and 2 APCR),
peripheral artery occlusion (n=3; l PC, l APCR, and l
double defect), and bowels infarction (n=2; l PC and l PS).
The overall incidence of arterial thrombosis was 0.12%/y. It
was 0.09%/y for AT, 0.13%/y for PC, 0.12%/y for PS,
0.11%/y for APCR, and 0.20%/y for the group with a double
defect. We found a positive relation between age and inci-
dence of arterial thrombosis (0% for age £20 years, 0.08%/y
for the age ränge of 21 to 40 years, 0.27%/y for the age ränge
of 41 to 60 years, and 0.78 %/y for age >60 years), but the
number of cases was too small to draw any firm conclusion
(0, 6, 11, and 9, respectively, in the 4 age groups). We
obtained similar numbers for both men and women (data not
shown).

































Risk of Thrombosis in High-Risk Situations
Information about risk factors at the time of the first episode of
VTE was obtained from 95 of 106 symptomatic relatives (90%).
Idiopathic thrombosis occurred in 30 of the 95 cases (32%) (12
of 32 AT [38%], 6 of 20 PC [30%], 3 of 15 PS [20%], 8 of 25
APCR [32%], and l of 3 double defect [33%]), and a triggering
factor was associated with 65 of the 95 cases of thromboembolic
events (68%) (20 of 32 AT [62%], 14 of 20 PC [70%], 12 of 15
PS [80%], 17 of 25 APCR [68%], and 2 of 3 double defect
[67%]). Surgery preceded VTE in 28 of 95 cases (29%),
puerperium in 12 of 56 (21%), pregnancy in 10 of 56 (18%),
whereas immobilization was found in 10 of 95 cases (l l %), oral
contraceptives in 6 of 56 (11%), and plaster in 6 of 95 (6%).
Table 6 shows the distribution of risk factors among the different
groups of inherited defects. In most cases of secondary VTE, the
event was associated with l risk factor only. A concomitant
association with 2 risk factors was found in l patient with AT
(oral contraceptives and plaster), 2 patients with PC (puerperium
and gynecologic surgery), l patient with PS (orthopedic surgery
and immobilization), l patient with APCR (general surgery and
immobilization), and l patient with a double defect (general
surgery and immobilization). In l subject with PC deficiency, a
concomitant association with 3 risk factors was present (ortho-
pedic surgery, immobilization, and oral contraceptives).
Discussion
One of the main objectives of this study was to establish the
lifetime risk for VTE in subjects with l of the 4 main
Coagulation defects related to inherited thrombophilia (AT,
PC, PS, and APCR) and to compare the clinical features of
the different defects. Particular attention was taken to include
only families with documented inherited defects and to avoid





























*For each subject only the first thrombotic event has been considered.
tPer 100 patient-years.
group.
*For each subject only the first thrombotic event has been considered.
tPer 100 patient-years.
group.
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Thrombosis-free survival curves
(Kaplan-Meier method) of relatives with
AT(—), PC (---), or PS (--)defi·
ciency or APCR (· · ·). In all the curves
each Step represents a VTE event.
10 20 30 40 50 60 70
Age (years)
selection bias, by considering only relatives. Of the 1143
subjects of whom we received data, 746, from 233 kindreds,
fulfilled the inclusion criteria. The 513 relatives were in-
cluded in the study.
The lifetime risk for VTE in the AT group was 4-fold
greater than in the APCR group, 3-fold than in the PS
group, and 2-fold than in the PC group. It was 2-fold
80 90 100
greater in PC than in APCR, whereas no difference was
found between the PS and APCR groups. The probability
that a subject with APCR will be free of thrombosis at the
age of 45 is 0.88, compared with 0.59 for AT, 0.74 for PC.
and 0.79 for PS. This finding is in agreement with the
study of Svensson and Dahlbäck,7 who found a probability
of «0.89 to be free of VTE at age 45 in his APCR relatives
































































































































Data are ratlos of numbers of patients to
parentheses.
*0nly female cases.
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group. A similar result was obtained recently in a retp-
spective family study,14 in which the estimated anniial
incidence of VTE in APCR carriers was 0.45%, near that
found in our study (0.30%). These figures may explain
previous observations15 that homozygosity for APCR gives
a lower risk of thrombosis than homozygosity for PC and
PS, which frequently causes severe neonatal thrombo-
sis.16·17 Also in our study, all 3 homozygous patients with '
PC deficiency were symptomatic, and l of them had deep
vein thrombosis at birth; of the 11 homozygous patients -
with APCR, 6 were symptomatic and 5 were still asymp-
tomatic (2 of them were >60 years old), despite their
exposure to many risk factors. A higher risk for VTE in AT
carriers than in subjects with PC and PS deficiency was
also reported in previous studies,18·19 äs well äs in a recent
single-center prospective study but with a small number of
cases.20
One possible limitation in our study is that cases were
not consecutive, and selection criteria could have been
different over the years for each single center and in
different centers. This implies that the apparent severity of
thrombophilia depends on how families were selected.
Carriers of common inherited defects (eg, APCR) are
easier to find than those with rare defects (eg, AT, PC, and
PS) and selection on severity may be less strong; then they
will appear less severely affected. Evidence that selection
is crucial comes from the reported absence of thrombosis
in blood donors with PC deficiency and their relatives,21
from the different age at onset because of patient selec-
tion,22 from some case reports about homozygous PC-
deficient carriers with absence or moderately severe clin-
ical Symptoms,23·24 and from those studies that report a
different risk of thrombosis in patients with an association
of 2 inherited coagulation abnormalities.25"29 In our study
this problem has been reduced by focusing our attention
only on families in which the proband had had at least l
episode of VTE. The results might be different if we
consider unselected cases, äs reported in previous stud-
ies.8·10 But the main disadvantage of selecting consecutive
cases is the time demanded if an appropriate number of
subjects with rare defects must be selected.
Another possible limitation is the nature of this study
(multicenter retrospective). This design could have influ-
enced our conclusions in 2 ways, ie, (1) the laboratory
diagnosis has been made by using different assays during
different periods of time and in different centers, and
(2) there could be a possible recall bias for thrombotic
events, if they are not objectively documented, and for
exposure to risk factors. The inclusion criterion of at least
2 family members with the coagulation defect suggests that
we avoided possible acquired defects, also in those situa-
tions in which we did not have confirmation by genetic
tests. Furthermore, all centers are proficient in laboratory
quality control exercises in which they regularly partici-
pate. Recall bias should be equally represented in all the
genetic defects for cases of thrombosis and exposure to
risk factors. In fact, selection of only relatives with a
"certain" episode of VTE (79 of 106) did not affect
substantially the results.
We did not contemplate a parallel study of VTE inci-
dence in individuals without genetic defects. To get a
general idea of the different risk for VTE between subjects
with a genetic defect and the general population, we
considered the study by Nordström et al,30 which showed
in a community-wide study that the annual incidence of
first VTE is «1.0 per 1000. Taking this example äs a
baseline risk, the risk for VTE for AT deficiency carriers
would be «ll-fold greater than this, whereas it would be
5-fold for PC and PS deficiency carriers and 3-fold for
APCR carriers.
The incidence rate of VTE could be underestimated
because some asymptomatic subjects might have had
subclinical thrombosis that no one was able to diagnose.
This problem has also been postulated by Anderson et al,31
but there is no particular reason to think that it is
represented more in one inherited defect than in the others.
The mean age of relatives at the time of the first episode
of VTE was similar in all the groups of coagulation
defects, excluding that with a double defect. This is in
agreement with recent reports regarding the age at onset in
relatives with APCR and PC.22 In most of the other studies
the age at onset of VTE was lower than the age in our
study, and the prevalence of symptomatic subjects was
higher, perhaps because both probands and relatives were
considered in the analysis, leading to a selection bi-
as.18·19·32·33 Moreover, the age of relatives at the time of the
first episode of VTE and the incidence of thrombosis can
change according to the age of the probands at the first
VTE event (Table 2). This could be because a selection of
subjects from families with a different risk for VTE
(higher in families in which the proband had had the
thrombosis at a younger age), probably because there is a
co-segregation of other unknown inherited defects.
This study gives a clear demonstration that the risk for
VTE increases with age after age 20, but it becomes
constant after age 40. This is in agreement with the finding
that the mean age at onset of VTE is in the fourth decade.
Ridker et al34 also demonstrated an increased risk for VTE
with age in factor V:Q506 carriers. Women had the peak of
risk earlier than men (age ränge, 21 to 40 years versus 41
to 60 years); pregnancy/puerperium and oral contracep-
tives play an important role in the earlier onset of VTE for
women.
The type of first thrombotic manifestation was different
among the groups of inherited defects. In the AT group,
VTE was mostly represented, SVT was rare, and arterial
thrombosis absent, whereas in PC and PS groups the
prevalence of SVT and arterial thrombosis was higher, äs
described in previous studies.18·19·32 In patients with
APCR, the prevalence of VTE and that of SVT were near
those in PC- and PS-deficient patients (50% and 26%,
respectively), in agreement with a recent study35 that
showed similar clinical manifestations in APCR, PC, and
PS deficiency, despite a later occurrence of the first event
in APCR.
We conclude that the risk for VTE in carriers of
inherited AT, PC, and PS deficiencies or APCR is related
to age. The age at onset is earlier in women than in men.
The risk seems to be higher in AT deficiency than in the
other inherited coagulation abnormalities. Selection of
families in which probands have different ages at onset of
VTE can affect the age at onset and the incidence of
. l
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thrombosis of relatives coming from those different fam-
ilies. Recruiting relatives from kindreds with inherited
thrombophilic defects can lead to an overestimation of the
thrombotic risk because of such mutations, äs further
unknown genetic defects may co-segregate in these fami-
lies. In our study we considered family members of
patients with at least l episode of VTE; 90% of the first
events in the index cases occurred before age 45. There-
fore, it should be emphasized that these findings must be
applied only to familial thrombophilia, but for consecutive
cases the results might be different. Because in our study
the follow-up ended in April 1996, we could not consider
the other common genetic determinant of VTE, the novel
G20210A pro thrombin gene mutation.36 In the near future
we will evaluate in a family study the importance of this
mutation, alone and in combination with the other defects,
äs a cause of VTE.
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